Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 11/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909994 | 0.86 | PDE5A (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2910606 | 0.80 | DRD4 (0.47) | TDP1 | |
| SCHEMBL6368168 | 0.77 | NTRK1 (0.49) | PDE5AAAK1 | |
| SCHEMBL2908964 | 0.76 | CACNA1H (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2907909 | 0.76 | KDM4E (0.45) | TDP1 | |
| SCHEMBL2903412 | 0.76 | KDM4E (0.44) | RHEBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6656239 | 0.67 | CACNA1H (0.45) | AAK1 | |
| SCHEMBL5259625 | 0.65 | PDE3B (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9688929 | 0.65 | ATP4A (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31212264 | 0.65 | NQO2 (0.33) | RHEBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400510-B1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | KOWA CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-7135473-B2 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1400510-A1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6632810-B2 | Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation | KOWA CO., LTD. (JP) | 2003-10-14 | — | — | US | disclosed |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | RHEB 4081/4885GRIN2D 833/4885GRIN3B 388/4885 |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | RHEB 4081/4885GRIN2D 833/4885GRIN3B 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.